ProMIS Neurosciences Unveils New Vaccine Strategy for Targeting Toxic Amyloid-Beta Oligomers at 2024 Alzheimer's Conference

Recent preclinical findings have showcased promising results for ProMIS Neurosciences Inc.'s novel approach in developing an Alzheimer’s disease (AD) vaccine, highlighting strong antibody responses with no significant pro-inflammatory T cell responses against amyloid-beta oligomers (AβO). This data was presented at the 2024 Alzheimer’s Association International Conference (AAIC), signaling a potential breakthrough in AD treatment.

ProMIS Neurosciences Inc., a biotech company based in Cambridge, Massachusetts, and Toronto, Ontario, is dedicated to creating antibody therapeutics aimed at toxic misfolded proteins that contribute to neurodegenerative diseases such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company's proprietary computational platform has identified four AβO-specific conformational B cell epitopes as candidates for an AD vaccine. This innovative platform also allowed the company to determine the optimal vaccine configuration, aimed at maximizing binding to toxic oligomer-rich low molecular weight fractions of soluble AD brain extracts.

The company's study revealed that vaccines targeting AβO-restricted B cell epitopes elicited strong antibody responses without triggering measurable pro-inflammatory T cell responses against Aβ. Immunization with epitope 301, which is the target of ProMIS’s lead product PMN310, alone was sufficient to produce a maximal antibody response against brain AβO.

Neil R. Cashman, M.D., Chief Scientific Officer and Co-Founder of ProMIS Neurosciences, emphasized the potential advantages of their PMN310 antibody and AβO vaccine candidates. He noted that the preclinical data is particularly encouraging as it suggests that an AD vaccine capable of inducing an effective antibody response against pathogenic Aβ could be used both as a preventive measure for individuals at risk and therapeutically to inhibit disease progression in diagnosed patients.

The poster presentation at the AAIC, titled "Novel approach to optimization of Alzheimer’s vaccine configuration for maximal targeting of toxic amyloid-beta oligomers," provided further details on the study. The presentation highlighted the company's innovative approach in optimizing the vaccine configuration to target toxic AβO, a major pathogenic species in AD.

ProMIS Neurosciences Inc. utilizes a unique thermodynamic and computational discovery platform called ProMIS™ and Collective Coordinates for predicting novel targets on misfolded proteins. This platform enables the company to develop targeted antibody therapeutics for various neurodegenerative diseases. ProMIS Neurosciences continues to advance its research and development efforts, with offices strategically located in Toronto and Cambridge.

The potential of the company's novel vaccine approach could significantly impact the treatment landscape of AD, providing hope for both preventive and therapeutic measures. As the company progresses with its clinical developments, particularly with PMN310, it aims to address the critical need for effective treatments against neurodegenerative diseases.

Overall, the preclinical data presented by ProMIS Neurosciences underscores the promising potential of their novel approach in developing an AD vaccine. The company remains focused on advancing its research to provide innovative therapeutic solutions for neurodegenerative diseases, leveraging its proprietary discovery platform and strong scientific foundation.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!